From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Pembrolizumab for Management of Patients With NSCLC and Brain Metastases: Long-Term Results and Biomarker Analysis From a Non-Randomised, Open-Label, Phase 2 Trial

Last Updated: Wednesday, January 27, 2021

An open-label, phase 2 trial found that pembrolizumab has activity in brain metastases from NSCLC with PD-L1 expression at least 1% and is safe in selected patients with untreated brain metastases.

The Lancet Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement